ArticleBiomacromolecules2013
Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition.
Article in Biomacromolecules, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- A Facile and Promising Delivery Platform for siRNA to Solid Tumors.Molecules (Basel, Switzerland) · 2024Article
- Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors.NAR cancer · 2024Article
- Marked increase in tumor transfection with a truncated branched polymer.The journal of gene medicine · 2022Article
- Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization.Pharmaceutics · 2020Review
- Enhanced tumor uptake and activity of nanoplex-loaded doxorubicin.Biochemical and biophysical research communications · 2019Article
- Targeted Delivery of siRNA Therapeutics to Malignant Tumors.Journal of drug delivery · 2017Review
- Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.Advanced drug delivery reviews · 2016Review
- Systematic Comparisons of Formulations of Linear Oligolysine Peptides with siRNA and Plasmid DNA.Chemical biology & drug design · 2016Article
- MicroRNA Targeting to Modulate Tumor Microenvironment.Frontiers in oncology · 2016Review
- siRNA nanoparticles: the future of RNAi therapeutics for oncology?Nanomedicine (London, England) · 2014Article
- Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma.Oncotarget · 2014Article
- Enhancement of antifungal activity by integrin-targeting of branched histidine rich peptides.Journal of drug targeting · 2014Article
- New aspects of gene-silencing for the treatment of cardiovascular diseases.Pharmaceuticals (Basel, Switzerland) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
We characterized in this study the pharmacokinetics and antitumor efficacy of histidine-lysine (HK):siRNA nanoplexes modified with PEG and a cyclic RGD (cRGD) ligand targeting αvβ3 and αvβ5 integrins. With noninvasive imaging, systemically administered surface-modified HK:siRNA nanoplexes showed nearly 4-fold greater blood levels, 40% higher accumulation in tumor tissue, and 60% lower luciferase activity than unmodified HK:siRNA nanoplexes. We then determined whether the surface-modified HK:siRNA nanoplex carrier was more effective in reducing MDA-MB-435 tumor growth with an siRNA targeting Raf-1. Repeated systemic administration of the selected surface modified HK:siRNA nanoplexes targeting Raf-1 showed 35% greater inhibition of tumor growth than unmodified HK:siRNA nanoplexes and 60% greater inhibition of tumor growth than untreated mice. The improved blood pharmacokinetic results and tumor localization observed with the integrin-targeting surface modification of HK:siRNA nanoplexes correlated with greater tumor growth inhibition. This investigation reveals that through control of targeting ligand surface display in association with a steric PEG layer, modified HK: siRNA nanoplexes show promise to advance RNAi therapeutics in oncology and potentially other critical diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.